CN1304051C - P－选择素糖蛋白配体1的调节剂 - Google Patents

P－选择素糖蛋白配体1的调节剂 Download PDF

Info

Publication number
CN1304051C
CN1304051C CNB028029844A CN02802984A CN1304051C CN 1304051 C CN1304051 C CN 1304051C CN B028029844 A CNB028029844 A CN B028029844A CN 02802984 A CN02802984 A CN 02802984A CN 1304051 C CN1304051 C CN 1304051C
Authority
CN
China
Prior art keywords
cells
psgl
cell
antibody
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028029844A
Other languages
English (en)
Chinese (zh)
Other versions
CN1473052A (zh
Inventor
林荣华
吴忠勋
徐碧岭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abgenomics Corp
Original Assignee
Abgenomics Cooperatief UA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Cooperatief UA filed Critical Abgenomics Cooperatief UA
Publication of CN1473052A publication Critical patent/CN1473052A/zh
Application granted granted Critical
Publication of CN1304051C publication Critical patent/CN1304051C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
CNB028029844A 2001-08-03 2002-03-13 P－选择素糖蛋白配体1的调节剂 Expired - Fee Related CN1304051C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31019601P 2001-08-03 2001-08-03
US60/310,196 2001-08-03
US10/051,497 US7744888B2 (en) 2001-08-03 2002-01-18 Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US10/051,497 2002-01-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200710003904XA Division CN101045161B (zh) 2001-08-03 2002-03-13 P-选择素糖蛋白配体1的调节剂

Publications (2)

Publication Number Publication Date
CN1473052A CN1473052A (zh) 2004-02-04
CN1304051C true CN1304051C (zh) 2007-03-14

Family

ID=26729479

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028029844A Expired - Fee Related CN1304051C (zh) 2001-08-03 2002-03-13 P－选择素糖蛋白配体1的调节剂
CN200710003904XA Expired - Fee Related CN101045161B (zh) 2001-08-03 2002-03-13 P-选择素糖蛋白配体1的调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200710003904XA Expired - Fee Related CN101045161B (zh) 2001-08-03 2002-03-13 P-选择素糖蛋白配体1的调节剂

Country Status (19)

Country Link
US (3) US7744888B2 (https=)
EP (2) EP1411982B1 (https=)
JP (3) JP4815101B2 (https=)
KR (1) KR100850731B1 (https=)
CN (2) CN1304051C (https=)
AT (2) ATE411045T1 (https=)
AU (1) AU2002305041B2 (https=)
CA (1) CA2428822C (https=)
CY (2) CY1108701T1 (https=)
DE (1) DE60229394D1 (https=)
DK (2) DK1411982T3 (https=)
ES (2) ES2376948T3 (https=)
IL (4) IL160168A0 (https=)
MX (1) MXPA04001047A (https=)
NO (2) NO333456B1 (https=)
NZ (1) NZ531199A (https=)
PT (2) PT1411982E (https=)
TW (1) TWI327070B (https=)
WO (1) WO2003013603A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
CA2538284C (en) * 2003-09-15 2015-10-20 Rong-Hwa Lin Modulators of p-selectin glycoprotein ligand 1
WO2005047320A2 (en) * 2003-11-12 2005-05-26 Wisconsin Alumni Research Foundation Equine p-selection glycoprotein ligand-1 and uses thereof
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
AU2012201999C1 (en) * 2004-05-10 2016-05-12 Abgenomics Cooperatief U.A. Antibodies
CN1985000B (zh) * 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
WO2009140623A2 (en) * 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
PT3166636T (pt) * 2014-07-08 2021-06-29 Sanford Burnham Med Res Inst Moduladores de psgl-1 e utilizações dos mesmos
SG11201805557SA (en) 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
US20170241415A1 (en) * 2016-02-19 2017-08-24 Muzan, Inc. Sanitary check valve
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
WO2020224450A1 (en) * 2019-05-03 2020-11-12 The University Of Hong Kong Method for peritoneal metastatic cell detection and isolation thereof
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
WO2025168211A1 (en) * 2023-02-10 2025-08-14 Novo Nordisk A/S P-selectin peptide ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840679A (en) * 1992-10-23 1998-11-24 Genetics Institute, Inc. Method of inhibiting P-selectin ligand activity
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
NZ261991A (en) 1993-01-25 1998-04-27 Dana Farber Cancer Inst Inc Chimeric l and p selectin made by exchange of domains, uses thereof
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
EP0850243B1 (en) 1995-08-03 2003-10-08 Board Of Regents Of The University Of Oklahoma o-glycan inhibitors of selectin mediated inflammation
JPH09227410A (ja) 1996-02-21 1997-09-02 Sumitomo Pharmaceut Co Ltd 臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
MXPA01004310A (es) 1998-10-30 2003-06-06 Cbr Lab Inc Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5840679A (en) * 1992-10-23 1998-11-24 Genetics Institute, Inc. Method of inhibiting P-selectin ligand activity

Also Published As

Publication number Publication date
CY1112966T1 (el) 2016-04-13
EP1411982A4 (en) 2004-10-06
DK1411982T3 (da) 2009-02-16
US8557579B2 (en) 2013-10-15
ATE531734T1 (de) 2011-11-15
IL210557A0 (en) 2011-03-31
DE60229394D1 (en) 2008-11-27
US8298540B2 (en) 2012-10-30
MXPA04001047A (es) 2005-02-17
PT1411982E (pt) 2008-12-24
JP2004521958A (ja) 2004-07-22
ES2316569T3 (es) 2009-04-16
CY1108701T1 (el) 2014-04-09
CN101045161A (zh) 2007-10-03
IL160168A0 (en) 2004-07-25
WO2003013603A8 (en) 2004-06-10
NZ531199A (en) 2004-11-26
ATE411045T1 (de) 2008-10-15
KR20040054670A (ko) 2004-06-25
EP1985634B1 (en) 2011-11-02
US20030049252A1 (en) 2003-03-13
NO334850B1 (no) 2014-06-16
IL204030A0 (en) 2011-08-01
AU2002305041B2 (en) 2005-11-10
CN1473052A (zh) 2004-02-04
US20130011861A1 (en) 2013-01-10
HK1065489A1 (en) 2005-02-25
CN101045161B (zh) 2010-06-16
HK1124624A1 (en) 2009-07-17
NO20040460L (no) 2004-02-24
JP2008260759A (ja) 2008-10-30
DK1985634T3 (da) 2012-02-20
ES2376948T3 (es) 2012-03-21
IL160168A (en) 2011-02-28
IL204030A (en) 2014-11-30
US20090304709A1 (en) 2009-12-10
EP1411982A1 (en) 2004-04-28
CA2428822C (en) 2014-10-28
NO333456B1 (no) 2013-06-10
US7744888B2 (en) 2010-06-29
EP1985634A1 (en) 2008-10-29
KR100850731B1 (ko) 2008-08-06
CA2428822A1 (en) 2003-02-20
TWI327070B (en) 2010-07-11
JP2012092144A (ja) 2012-05-17
WO2003013603A1 (en) 2003-02-20
EP1411982B1 (en) 2008-10-15
JP4815101B2 (ja) 2011-11-16
PT1985634E (pt) 2012-02-07
NO20130069L (no) 2004-02-24

Similar Documents

Publication Publication Date Title
CN1304051C (zh) P－选择素糖蛋白配体1的调节剂
AU2002305041A1 (en) Modulators of P-selectin glycoprotein ligand 1
CN1227494A (zh) T-bam(cd40l)技术在治疗涉及平滑肌细胞的疾病中的治疗应用
US20080248011A1 (en) Methods for Isolating Monocytes
RU2407539C2 (ru) Модуляторы р-селектин гликопротеин лиганда 1
HK1065489B (en) Modulators of p-selectin glycoprotein ligand 1
HK1124624B (en) Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease
EA041126B1 (ru) Антитела и полипептиды, направленные против cd127
MXPA06002968A (en) Modulators of p-selectin glycoprotein ligand 1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: AIBIJINOMIX COOPERATION CO.,LTD.

Free format text: FORMER OWNER: ABGENOMICS INTERNATIONAL CO., LTD.

Effective date: 20091225

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091225

Address after: Amsterdam

Patentee after: Abgenomics Corp.

Address before: Taipei City, Taiwan, China

Patentee before: Univ Nat Taiwan

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070314

Termination date: 20210313

CF01 Termination of patent right due to non-payment of annual fee